Last month's edition of The BioPharm Bulletin contained an error in the article, "Promise and Challenges of Biotech Vaccines."
Last month’s edition of TheBioPharm Bulletin contained an error in the article, “Promise and Challenges of Biotech Vaccines.” The 6th line from the end of the article should have read, “Deshmukh cited the example of the Prevnar vaccine, which requires a total of 14 or 15 separate processes, to make seven different polysaccharides and a carrier protein, and then seven conjugates.”
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.